Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Boosted by Barclays PLC

Barclays PLC lifted its position in Royalty Pharma plc (NASDAQ:RPRX) by 17.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 363,308 shares of the biopharmaceutical company’s stock after buying an additional 54,421 shares during the period. Barclays PLC owned approximately 0.06% of Royalty Pharma worth $9,269,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Sterling Capital Management LLC boosted its holdings in Royalty Pharma by 30.4% during the fourth quarter. Sterling Capital Management LLC now owns 34,595 shares of the biopharmaceutical company’s stock worth $883,000 after buying an additional 8,071 shares in the last quarter. APG Asset Management US Inc. bought a new stake in shares of Royalty Pharma during the 4th quarter worth $201,000. Raymond James Financial Inc. acquired a new position in shares of Royalty Pharma in the 4th quarter worth $19,990,000. APG Asset Management N.V. raised its position in shares of Royalty Pharma by 4.8% during the fourth quarter. APG Asset Management N.V. now owns 382,906 shares of the biopharmaceutical company’s stock worth $9,433,000 after purchasing an additional 17,406 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Royalty Pharma by 33.2% during the fourth quarter. Invesco Ltd. now owns 957,893 shares of the biopharmaceutical company’s stock valued at $24,436,000 after purchasing an additional 238,508 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX stock opened at $32.19 on Wednesday. The firm has a 50 day simple moving average of $32.56 and a 200 day simple moving average of $29.34. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock has a market cap of $18.56 billion, a P/E ratio of 22.20, a P/E/G ratio of 2.31 and a beta of 0.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.73%. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several recent analyst reports. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.